Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,455Revenue (TTM) $M463Net Margin (%)14.0Altman Z-Score7.6
Enterprise Value $M1,403EPS (TTM) $2.0Operating Margin %21.9Piotroski F-Score7
P/E(ttm)23.1Beneish M-Score-2.5Pre-tax Margin (%)21.7Higher ROA y-yN
Price/Book4.110-y EBITDA Growth Rate %8.0Quick Ratio1.7Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %18.4Current Ratio3.5Lower Leverage y-yY
Price/Free Cash Flow33.2y-y EBITDA Growth Rate %22.4ROA % (ttm)12.4Higher Current Ratio y-yY
Dividend Yield %--PEG1.3ROE % (ttm)20.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M32.2ROIC % (ttm)23.9Gross Margin Increase y-yY

Gurus Latest Trades with CBM

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CBMThird Avenue Management 2016-03-31 Buy 0.13%$31.12 - $47.09
($39.54)
$ 45.2614%New holding76,681
CBMJoel Greenblatt 2016-03-31 Sold Out -0.06%$31.12 - $47.09
($39.54)
$ 45.2614%Sold Out0
CBMJoel Greenblatt 2015-12-31 Reduce-0.01%$40.43 - $53.63
($48.24)
$ 45.26-6%Reduce -19.35%110,565
CBMJoel Greenblatt 2015-09-30 Reduce-0.05%$39.57 - $53.82
($46.78)
$ 45.26-3%Reduce -48.98%137,090
CBMJoel Greenblatt 2015-06-30 Add0.08%$35.71 - $46.24
($41.39)
$ 45.269%Add 341.54%268,701
CBMJoel Greenblatt 2015-03-31 Reduce$21.34 - $39.63
($29.57)
$ 45.2653%Reduce -22.55%60,855
CBMJoel Greenblatt 2014-12-31 Buy 0.01%$16.33 - $24.12
($21.29)
$ 45.26113%New holding78,575
CBMJoel Greenblatt 2013-03-31 Sold Out -0.09%$11.27 - $12.79
($11.93)
$ 45.26279%Sold Out0
CBMJoel Greenblatt 2012-12-31 Buy 0.09%$9.34 - $13.96
($11.38)
$ 45.26298%New holding142,352
CBMJoel Greenblatt 2012-09-30 Sold Out -0.02%$9.01 - $13.01
($11.05)
$ 45.26310%Sold Out0
CBMJoel Greenblatt 2012-06-30 Buy 0.02%$5.96 - $9.16
($7.07)
$ 45.26540%New holding30,208
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBM is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CBM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KORB WILLIAM BDirector 2016-07-11Sell3,420$55-17.71view
KORB WILLIAM BDirector 2016-06-08Sell4,142$52.47-13.74view
KORB WILLIAM BDirector 2016-06-01Sell8,000$51.06-11.36view
KLOSK STEVEN MPresident & CEO 2016-05-09Sell14,005$49-7.63view
KLOSK STEVEN MPresident & CEO 2016-05-05Sell16,430$49.13-7.88view
KORB WILLIAM BDirector 2016-05-03Sell8,000$49.09-7.8view
KLOSK STEVEN MPresident & CEO 2016-03-16Sell19,565$4110.39view
Grabowsky Louis J.Director 2016-03-15Buy750$40.112.87view
KORB WILLIAM BDirector 2016-03-10Sell8,000$41.389.38view
SARGEN GREGORYExecutive Vice President & CFO 2016-03-09Sell26,697$41.379.4view

Quarterly/Annual Reports about CBM:

News about CBM:

Articles On GuruFocus.com
Third Avenue Comments on Cambrex Corp May 27 2016 
Chip Rewey's Third Avenue Small-Cap Value Fund 2nd Quarter Commentary May 27 2016 
Royce Smaller-Companies Growth Fund Annual Letter Mar 19 2016 
Royce Smaller-Companies Growth Fund Shareholder Letter Sep 20 2015 
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Cambrex to Acquire PharmaCore Inc., to Expand Clinical Stage API Capabilities Sep 26 2016
6:46 am Cambrex to acquire privately-owned PharmaCore for approximately $25 mln Sep 26 2016
Cambrex to Acquire PharmaCore Inc., to Expand Clinical Stage API Capabilities Sep 26 2016
The Zacks Analyst Blog Highlights: Mylan, ANI Pharmaceuticals, Cambrex, PDL BioPharma and Innoviva Sep 14 2016
4 Biotech Stocks to Buy as Election Fever Rises Sep 13 2016
Advantages of Integrating Biocatalytic Transformations into Small Molecule Synthesis to be Presented... Sep 08 2016
What Makes XBiotech (XBIT) a Strong Sell? Sep 07 2016
Cambrex Announces Investment and Expansion to Large Scale, Multi-Purpose Manufacturing Capabilities... Sep 06 2016
Cambrex Announces Investment and Expansion to Large Scale, Multi-Purpose Manufacturing Capabilities... Sep 06 2016
Can Cambrex (CBM) Keep the Earnings Streak Alive This Quarter? Aug 31 2016
Cambrex (CBM) is Oversold: Can It Recover? Aug 30 2016
Cambrex to Present at Upcoming Investor Conferences in September Aug 26 2016
Cambrex to Present at Upcoming Investor Conferences in September Aug 26 2016
ETF’s with exposure to Cambrex Corp. : August 22, 2016 Aug 22 2016
Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline Aug 10 2016
Is Cambrex Corporation (CBM) a Great Growth Stock? Aug 04 2016
Cambrex Corp. :CBM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016 Aug 03 2016
CAMBREX CORP Financials Aug 03 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)